Leonteq Securities’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$889K Sell
60,000
-90,000
-60% -$644K 0.04% 249
2026
Q2
$624K Sell
150,000
-10,000
-6% -$38K 0.02% 357
2026
Q1
$562K Sell
160,000
-35,000
-18% -$112K 0.02% 388
2025
Q4
$532K Buy
195,000
+100,000
+105% +$231K 0.02% 445
2025
Q3
$206K Hold
95,000
– – 0.01% 602
2025
Q2
$163K Buy
+95,000
New +$236K 0.01% 608
2025
Q1
– Sell
-29,000
Closed -$150K – 1287
2024
Q4
$215K Sell
29,000
-11,000
-28% -$102K 0.01% 528
2024
Q3
$376K Hold
40,000
– – 0.03% 369
2024
Q2
$321K Buy
40,000
+9,800
+32% +$105K 0.02% 396
2024
Q1
$448K Sell
30,200
-19,800
-40% -$230K 0.03% 332
2023
Q4
$406K Buy
50,000
+8,587
+21% +$44.9K 0.02% 361
2023
Q3
$188K Buy
41,413
+30,609
+283% +$200K 0.01% 537
2023
Q2
$76.1K Buy
10,804
+8,473
+363% +$60.6K ﹤0.01% 743
2023
Q1
$14.2K Sell
2,331
-14,233
-86% -$98.2K ﹤0.01% 970
2022
Q4
$106K Buy
16,564
+8,542
+106% +$66.7K ﹤0.01% 663
2022
Q3
$76.9K Sell
8,022
-1,601
-17% -$18.5K ﹤0.01% 701
2022
Q2
$106K Sell
9,623
-261
-3% -$3.42K ﹤0.01% 673
2022
Q1
$165K Sell
9,884
-480
-5% -$7.42K 0.01% 630
2021
Q4
$198K Sell
10,364
-994
-9% -$21.9K 0.01% 627
2021
Q3
$280K Sell
11,358
-2,724
-19% -$64.2K 0.01% 519
2021
Q2
$366K Buy
14,082
+14,055
+52,056% +$365K 0.02% 452
2021
Q1
$855 Sell
27
-6
-18% -$249 ﹤0.01% 963
2020
Q4
$1.53K Buy
+33
New +$1.31K ﹤0.01% 948

Other funds holding IOVA

Leonteq Securities's IOVA Position: Q3 2026 in Review

Leonteq Securities reduced its Iovance Biotherapeutics (IOVA) stake by 60% in Q3 2026, selling an estimated $644K and leaving 60,000 shares worth $889K. The position accounts for 0.04% of the portfolio, ranked #249.

Leonteq Securities first reported a position in IOVA in Q4 2020 and has held it in 23 quarters since. 335 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Leonteq Securities held 60,000 shares of Iovance Biotherapeutics worth $889K as of Q3 2026.
  • Leonteq Securities sold 90,000 Iovance Biotherapeutics shares in Q3 2026, an estimated $644K.
  • Iovance Biotherapeutics made up 0.04% of Leonteq Securities's portfolio in Q3 2026, its #249 holding.
  • Leonteq Securities first reported a position in Iovance Biotherapeutics in Q4 2020 and has held it in 23 quarters since.
  • 335 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.